We claim:

1. A method comprising:

determining whether OX-2/CD200 is upregulated in a subject; and

administering to the subject a polypeptide that binds to OX-2/CD200 or an OX-2/CD200 receptor.

2. A method as in claim 1 wherein the step of administering a polypeptide comprises administering to the subject an antibody that binds to OX-2/CD200.

3. A method as in claim 1 wherein the step of administering a polypeptide comprises administering to the subject a monoclonal antibody that binds to OX-2/CD200.

4. A method as in claim 1 wherein the step of administering a polypeptide comprises administering to the subject an antibody that binds to an OX-2/CD200 receptor.

5. A method as in claim 1 wherein the step of administering a polypeptide comprises administering to the subject a monoclonal antibody that binds to an OX-2/CD200 receptor.

6. A method as in claim 1 wherein the step of administering a polypeptide comprises administering to the subject a polypeptide comprising one or more amino acid sequences selected from the group consisting of SEQ. ID. NO: 1, SEQ. ID. NO: 2, SEQ. ID. NO: 3, SEQ. ID. NO: 4, SEQ. ID. NO: 5, SEQ. ID. NO: 6, SEQ. ID. NO: 7, SEQ. ID. NO: 8, SEQ. ID. NO: 9, SEQ. ID. NO: 10, SEQ. ID. NO: 11, SEQ. ID. NO: 12, SEQ. ID. NO: 13, SEQ. ID. NO: 14, SEQ. ID. NO: 15, SEQ. ID. NO: 16, SEQ. ID. NO: 17, SEQ. ID. NO: 18, SEQ. ID. NO: 19, SEQ. ID. NO: 20, SEQ. ID. NO: 21, SEQ. ID. NO: 22, SEQ. ID. NO: 23, SEQ. ID. NO: 24, and SEQ. ID. NO: 25.

7. A method of treating a disease state in which OX-2/CD200 is upregulated comprising administering to a subject afflicted with a disease state in which OX-2/CD200 is upregulated a polypeptide that binds to OX-2/CD200 or to an OX-2/CD200 receptor.

8. A method as in claim 7 wherein the step of administering a polypeptide comprises administering to the subject an antibody that binds to OX-2/CD200.

9. A method as in claim 7 wherein the step of administering a polypeptide comprises administering to the subject a monoclonal antibody that binds to OX-2/CD200.

10. A method as in claim 7 wherein the step of administering a polypeptide comprises administering to the subject an antibody that binds to an OX-2/CD200 receptor.

11. A method as in claim 7 wherein the step of administering a polypeptide comprises administering to the subject a monoclonal antibody that binds to an OX-2/CD200 receptor.

12. A method as in claim 7 wherein the step of administering a polypeptide comprises administering to the subject a polypeptide comprising one or more amino acid sequences selected from the group consisting of SEQ. ID. NO: 1, SEQ. ID. NO: 2, SEQ. ID. NO: 3, SEQ. ID. NO: 4, SEQ. ID. NO: 5, SEQ. ID. NO: 6, SEQ. ID. NO: 7, SEQ. ID. NO: 8, SEQ. ID. NO: 9, SEQ. ID. NO: 10, SEQ. ID. NO: 11, SEQ. ID. NO: 12, SEQ. ID. NO: 13, SEQ. ID. NO: 14, SEQ. ID. NO: 15, SEQ. ID. NO: 16, SEQ. ID. NO: 17, SEQ. ID. NO: 18, SEQ. ID. NO: 19, SEQ. ID. NO: 20, SEQ. ID. NO: 21, SEQ. ID. NO: 22, SEQ. ID. NO: 23, SEQ. ID. NO: 24, and SEQ. ID. NO: 25.

13. A method of treating cancer comprising:

determining whether OX-2/CD200 is upregulated in a subject afflicted with cancer; and

administering to the subject a polypeptide that binds to OX-2/CD200 or an OX-2/CD200 receptor.

14. A method as in claim 13 wherein the step of administering a polypeptide comprises administering to the subject an antibody that binds to OX-2/CD200.

15. A method as in claim 13 wherein the step of administering a polypeptide comprises administering to the subject a monoclonal antibody that binds to OX-2/CD200.

16. A method as in claim 13 wherein the step of administering a polypeptide comprises administering to the subject an antibody that binds to an OX-2/CD200 receptor.

17. A method as in claim 13 wherein the step of administering a polypeptide comprises administering to the subject a monoclonal antibody that binds to an OX-2/CD200 receptor.

18. A method as in claim 13 wherein the step of administering a polypeptide comprises administering to the subject a polypeptide comprising one or more amino acid sequences selected from the group consisting of SEQ. ID. NO: 1, SEQ. ID. NO: 2, SEQ. ID. NO: 3, SEQ. ID. NO: 4, SEQ. ID. NO: 5, SEQ. ID. NO: 6, SEQ. ID. NO: 7, SEQ. ID. NO: 8, SEQ. ID. NO: 9, SEQ. ID. NO: 10, SEQ. ID. NO: 11, SEQ. ID. NO: 12, SEQ. ID. NO: 13, SEQ. ID. NO: 14, SEQ. ID. NO: 15, SEQ. ID. NO: 16, SEQ. ID. NO: 17, SEQ. ID. NO: 18, SEQ. ID. NO: 19, SEQ. ID. NO: 20, SEQ. ID. NO: 21, SEQ. ID. NO: 22, SEQ. ID. NO: 23, SEQ. ID. NO: 24, and SEQ. ID. NO: 25.

19. A method of treating CLL comprising:

determining whether OX-2/CD200 is upregulated in a subject afflicted with CLL; and

administering to the subject a polypeptide that binds to OX-2/CD200 or an OX-2/CD200 receptor.

20. A method as in claim 19 wherein the step of administering a polypeptide comprises administering to the subject an antibody that binds to OX-2/CD200.

21. A method as in claim 19 wherein the step of administering a polypeptide comprises administering to the subject a monoclonal antibody that binds to OX-2/CD200.

22. A method as in claim 19 wherein the step of administering a polypeptide comprises administering to the subject an antibody that binds to an OX-2/CD200 receptor.

23. A method as in claim 19 wherein the step of administering a polypeptide comprises administering to the subject a monoclonal antibody that binds to an OX-2/CD200 receptor.

24. A method as in claim 19 wherein the step of administering a polypeptide comprises administering to the subject a polypeptide comprising one or more amino acid sequences selected from the group consisting of SEQ. ID. NO: 1, SEQ. ID. NO: 2, SEQ. ID. NO: 3, SEQ. ID. NO: 4, SEQ. ID. NO: 5, SEQ. ID. NO: 6, SEQ. ID. NO: 7, SEQ. ID. NO: 8, SEQ. ID. NO: 9, SEQ. ID. NO: 10, SEQ. ID. NO: 11, SEQ. ID. NO: 12, SEQ. ID. NO: 13, SEQ. ID. NO: 14, SEQ. ID. NO: 15, SEQ. ID. NO: 16, SEQ. ID. NO: 17, SEQ. ID. NO: 18, SEQ. ID. NO: 19, SEQ. ID. NO: 20, SEQ. ID. NO: 21, SEQ. ID. NO: 22, SEQ. ID. NO: 23, SEQ. ID. NO: 24, and SEQ. ID. NO: 25.